Press Release on Consolidated Financial Results for the quarter ended June 30, 2026
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 21 Jul 2026, 04:54 PM IST · BSE ID: 19fe32d5-f7db-45db-9b3f-9e220be8e43c
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's quarterly revenue fell by 22.6% to ₹4,182 Mn, and net profit decreased by 11.7% to ₹1,199 Mn.
🤖 AI Summary
- Anthem Biosciences reported Q1FY27 Consolidated Revenue from Operations at ₹4,182 Mn, down 22.6% YoY.
- Profit after tax (PAT) for Q1FY27 was ₹1,199 Mn, a decrease of 11.7% compared to Q1FY26.
- EBITDA for the quarter stood at ₹1,755 Mn, with EBITDA margins at 39.6% for Q1FY27.
- CRDMO business revenues were ₹3,408 Mn, and Specialty Ingredients revenues were ₹774 Mn in Q1FY27.
- Other Income increased by 9.2% YoY to ₹249 Mn for the quarter ended June 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations
₹4,182 Mn
-22.6%
CRDMO Revenue
₹3,408 Mn
-24.7%
Specialty Ingredients Revenue
₹774 Mn
-11.5%
Total Revenues
₹4,431 Mn
-21.3%
Profit after tax
₹1,199 Mn
-11.7%
🏢 How This Affects the Company
Consolidated Revenue from Operations decreased by 22.6% YoY, impacting the scale of the company's core CRDMO and Specialty Ingredients businesses.
Profit after tax decreased by 11.7% YoY to ₹1,199 Mn, while EBITDA decreased by 18.1% YoY to ₹1,755 Mn, indicating reduced profitability.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's Q1FY27 financial performance, which showed a decrease in revenue and profit after tax.
🔍
Management Signal
Management indicates that Q1FY27 results reflect timing shifts in key customer deliveries, with a focus on cost efficiencies and yield optimization to maintain margins.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — assess if revenue growth aligns with management's expectations for later half.
Earnings call on July 22, 2026, 11:30 am IST — listen for detailed business outlook.
Future disclosures on customer deliveries — track any updates on timing shifts.
MEDIUM RISK
Revenue and profit declines signal short-term operational challenges and execution risks.
💡 Investor Takeaway
Anthem Biosciences' Q1FY27 consolidated revenue from operations decreased by 22.6% YoY to ₹4,182 Mn. Profit after tax also declined by 11.7% YoY to ₹1,199 Mn, despite maintained EBITDA margins of 39.6% from Q1FY26.
⚖️ Strengths & Concerns
✅ Positives
- EBITDA margins for Q1FY27 were 39.6%, and PAT margins were 27.1%, demonstrating sustained profitability metrics.
- Other Income increased by 9.2% YoY to ₹249 Mn, contributing to total revenues for the quarter.
⚠️ Concerns
- Consolidated Revenue from Operations decreased by 22.6% YoY to ₹4,182 Mn, indicating a significant top-line contraction.
- CRDMO business revenue declined by 24.7% YoY to ₹3,408 Mn, affecting the primary revenue segment.
📅 Company Track Record
Anthem Biosciences' prior Q1 FY27 filing on the same date reported a similar net profit decrease of 11.7% YoY to ₹1,199 Mn. An earlier filing mentioned Q1 FY27 profit decreased to Rs. 1,020.09 Mn, which was subsequently revised. The company was incorporated on June 13, 2006.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Anthem Biosciences' consolidated revenue from operations for Q1FY27?
Anthem Biosciences reported consolidated revenue from operations of ₹4,182 Mn for the quarter ended June 30, 2026.
How much was the Profit after tax (PAT) for Anthem Biosciences in Q1FY27?
The Profit after tax (PAT) for Anthem Biosciences in Q1FY27 was ₹1,199 Mn, which is an 11.7% decrease compared to Q1FY26.
What were the EBITDA and PAT margins for Anthem Biosciences in Q1FY27?
Anthem Biosciences reported an EBITDA of ₹1,755 Mn with EBITDA margins at 39.6% and PAT margins at 27.1% for Q1FY27.
What were the revenues for Anthem Biosciences' CRDMO and Specialty Ingredients segments in Q1FY27?
In Q1FY27, the CRDMO business delivered ₹3,408 Mn in revenues, while Specialty Ingredients delivered ₹774 Mn in revenues.
Questions based on this BSE filing only. For information purposes.